Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

Bonesupport, Audiocast, Q2'26

By Inderes7/16/2026, 8:00 AM
Bonesupport

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Torbjörn Sköld
00:01 - 13:03

Thank you. Operator. Welcome, everyone, to the BONESUPPORT Q2 2026 Results Call. My name is Torbjörn Sköld, CEO of BONESUPPORT. With me here today is our CFO, Håkan Johansson, and together we will use the next 25 minutes to guide you through the Q2 presentation and then open the line for questions. Before starting the presentation, I would like to draw your attention to the disclaimers covering any forward-looking statements we will make today. So let's look at the financial and operational highlights of the quarter. Q2 reflected solid execution across the business. Net sales came in at 356 million Swedish krona, corresponding to a growth at constant exchange rates (CER) of 30% versus Q2 2025. Reported growth was 25%, showing that the currency impact on our figures for the quarter has decreased compared to the previous quarters. Our adjusted operating result, excluding incentive program effects, was 104 million Swedish kronor, corresponding to an adjusted operating margin of 29%. Reported operating result was 99 million SEK. We saw another quarter of solid cash generation, with operating cash flows reaching 67 million SEK after completing a share buy-back of 83 million SEK. This resulted in a cash position of 434 million SEK at quarter end. After a period of significant commercial investments, it's encouraging to see the strong operating margin together with continued strong cash flows, as confirmation of the scalability of our business model. We continue to see strong traction for CERAMENT in the US, with sales reaching 295 million SEK for the quarter, compared with 236 million SEK in Q2 2025. In Europe and the rest of the world, we saw solid momentum across all markets, with growth of 26% at constant exchange rates (CER) compared to Q2 2025. During the quarter, the regulatory process for CERAMENT V progressed according to plan within the framework of the De Novo process. If granted market authorization, CERAMENT V will constitute an entirely new product category, like CERAMENT G in 2022. Just as in the review of the De Novo application for CERAMENT G, both the Center for Drug Evaluation and Research and the Center for Devices and Radiological Health are involved, and the lead review team, which sorts under CDRH. Remains the same as during the 510(k) process. BONESUPPORT has continued the constructive dialogue with the FDA. Within the scope of the De Novo process, we are working purposefully to address the requested details and clarifications. Responses are to be submitted no later than the end of August. Progress on CERAMENT for spine continues to be solid. The CERAMENT BVF launch is on track, and the preparations for the studies on antibiotic-eluting CERAMENT follow plan, an important step as we continue expanding our portfolio of indications and applications. In Q2, US CMS proposed improved reimbursement for the use of CERAMENT G in complex orthopedic infection surgery and more specific identification codes for CERAMENT G. Now let's move to the sales development. Next slide, please. This chart shows total LTM reported sales in Swedish krona by quarter since 2019. In stacked bars per region and product category. As you can see, the launch momentum for CERAMENT G in the US is strong. Given that we keep bringing new, strong clinical studies and opening up new market segments and new indications, a product like CERAMENT G will remain in launch phase for many years to come. However, throughout 2025 and in the first half of 2026, we have seen a strong influence from the US dollar to Swedish krona depreciation, which influences the optics of the graph but not the in-market performance, as you will see in the slides later in the presentation. Last 12 months growth in Q2 of 21% in the graph corresponds to an even stronger 32% at constant exchange rates. US CERAMENT BVF LTM sales were flat year over year at constant exchange rates. In total, antibiotic-eluting CERAMENT grew by 40% over the last 12 months in the quarter at constant exchange rates. Next slide please. In the US, sales amounted to 295 million SEK, representing a growth of 31% at constant exchange rates. Growth of CERAMENT G was slightly lower than expected due to a handful of customers implementing restrictions in their usage of CERAMENT, so-called pre-approvals. This reduced the growth rate somewhat in the quarter. It is not new for customers who started using CERAMENT G more recently to temporarily limit usage while awaiting results. The restrictions are set by hospital administrations to keep short-term costs down. The demand and the need among treating clinicians remain intact and are growing. We have seen this pattern before when customers accelerate their use of CERAMENT G. Hospital administrations may, as a cost-driven response, introduce temporary restrictions. So-called growth of CERAMENT G. These hospitals continue to use CERAMENT G, albeit at a reduced level, which creates a good foundation for increasing usage. Again, using health economic arguments, the proposed changes to DRG codes announced by CMS during the quarter, with expected implementation in the fourth quarter, add further strength to these dialogues. Excluding the impact from these customers mentioned. We continue to experience strong growth of CERAMENT G, driven by both increased access through new accounts and new surgeons, as well as wider adoption among existing users. We see growth from all three prioritized platforms: foot and ankle, trauma, and arthroplasty. As part of our ambition to modernize an outdated standard of care in the US. We have opened one market segment after another, starting with foot and ankle, followed by trauma, and now moving into revision arthroplasty. Our market research presented at our Capital Markets Day indicates that around 60% of the revision arthroplasties receive some form of local antibiotics, mainly from PMMA and antibiotic powder. It also indicates that 80% of the surgeons in the survey found CERAMENT G appealing to highly appealing, and interest continues to grow for CERAMENT G in revision arthroplasty and periprosthetic joint infections (PJI), where the clinical needs remain substantial, and the evidence supporting our antibiotic-eluting technology has resonated strongly with surgeons. We've built a solid foundation for our spine strategy over the past quarters by establishing distributor coverage and preparing the market in Q2. We continued the early stage launch of CERAMENT BVF in spinal procedures with distributors actively engaging spine surgeons across both existing and new partnerships. The surge in access and early stages of adoption in spine follow plan and indicate the strength and potential of this segment; as this is a new clinical segment for us, more clinical data is needed to support broader market penetration. Importantly, the performance of CERAMENT BVF in spine will help confirm the value proposition for the CERAMENT platform, which will pave the way for future antibiotic-eluting CERAMENT launches. Our market research, also presented at our Capital Markets Day in April, points to strong clinical and market rationale for antibiotic-eluting CERAMENT in spinal procedures. Infection and reinfection prevention remain major unmet needs in spine surgery. 75% of surgeons already use local antibiotics for surgical treatment, and 86% use them for prophylaxis in at least some patients. The current standard of applying antibiotic powder without controlled delivery, often called dumping, is used by roughly 78% of the surgeons. Yet 82%. Consider that this approach is suboptimal, pointing to a clear gap between current practice and what surgeons believe is the right solution. In Q2, the US CMS, Centers for Medicare and Medicaid Services, announced a proposed ruling for full-year 2027 IPPS, including changes that improve payments for the use of CERAMENT G in the treatment of complex orthopedic infections such as periprosthetic joint infection, fracture-related infection, and diabetes-related bone infection. In parallel, CMS proposes the introduction of more specific procedure and identification codes for CERAMENT G. Although this is a proposed ruling. This is very positive for BONESUPPORT as it validates the uniqueness and value CERAMENT brings and reduces potential barriers for using CERAMENT in daily clinical practice. The company submitted additional clarifications to the CMS during the public comment period, aiming to tie the extra reimbursement specifically to on-label use of approved products in this category, where we currently hold the only approval. Strengthening our competitive moat. In parallel, we've prepared a rollout plan with supporting education and communication materials to fully capitalize on the ruling. A final decision from CMS is expected in late summer 2026, and the ruling is expected to come into effect as of October 1st, 2026. Now let's turn to Europe. Next slide please. Sales in EUROW came in at 61 million, representing 26% growth at constant exchange rates. While part of this reflects a softer comparison base in Q2 2025, it was still a very strong quarter. We saw strong development across our three market structures: direct, hybrid, and distributor markets. This model is well suited to the early stage the company is currently in. In our direct markets, the market conditions in Germany have stabilized and healthcare providers have adapted to the new normal. Following last year's market reforms, our investments in hybrid markets developed well, underlying continued potential ahead. In our distributed markets, we see large potential to increase our footprint by entering more countries. Meanwhile, the CERAMENT launch in India, with a focus on the private market, is going according to plan. We note volatility in the Middle East, where geopolitical unrest is affecting market presence and logistics in the short term. Now I will leave a deep dive into the numbers to Håkan.

Håkan Johansson
13:03 - 19:06

Thank you, Torbjörn. So net sales improved from 284 to 356 million, equalling a growth of 25% in reported sales growth, or 30% in constant exchange rates. Torbjörn has already spoken about the performance in the US and the major drivers behind the sales growth. But as the large movement in US dollars over time somewhat hides the true trajectory in the US. I would like to share the US sales performance in US dollars. Having CERAMENT G as the growth driver in the US. This slide shows the quarterly CERAMENT G sales in the US. In US dollars with continued solid performance despite the isolated headwinds already covered by Torbjörn. The contribution from the US segment improved by 35.8 million versus Q2 2025 and amounted to 140.2 million. The improved contribution relates to increased sales after the effect of increased costs. Selling and marketing expenses during the quarter amounted to 135.3 million, compared with 117.8 million in the previous year, of which sales commissions to distributors and fees amounted to 94.5 million, compared with 78.5 million in the same quarter last year. From the graph at the bottom of the screen, net sales are shown as bars and the gross margin as the orange marker. It can be noted that the gross margin remains stable and strong at 93.8%, with a slight decline in the quarter, mainly following the impact from tariffs which amounted to 1.5 million in comparison with the same quarter last year. In Europe and the rest of the world. A contribution of 16.8 million was reported, compared with 13.6 million the previous year. Selling and marketing expenses increased by 5.3 million, mainly related to the previously communicated commercial investments in the so-called Euro booster programme. From the lower graph and orange marker, a minor movement in gross margin can be noted, mainly impacted by market mix. Selling expenses, excluding sales commissions and fees, increased by 16.2 million compared with the previous year. Following the commercial investments in both the US and EUROW, investments aimed at future sales growth are driven both by market opportunities and by sustained high marketing activity. R&D remains at a stable level and is focused on strategic initiatives such as the market authorization submission for CERAMENT V in the US. Research and studies in spine, as well as future portfolio innovation and administrative expenses, excluding the effects from the long-term incentive programs, remained stable with an increase of 1.3 million in the quarter. The adjusted operating result amounted to 104.1 million, with only minor currency effects impacting. I will come back to this on a later slide. Gross margin is down following a 2.7 million inventory write-down regarding components and materials, as well as continued impact from U.S. tariffs. As mentioned previously, a 1.5 million impact compared with the same period last year. The difference between the adjusted and reported operating result reflects costs related to our long-term incentive programs, amounting to an expense of 14.5 million in the quarter, compared with an expense of 7.6 million in the previous year. As you can see from the previous slide, the increase in expense includes 1.6 million SEK relating to the long-term incentive program approved by the AGM in May 2025, which was included from the beginning of this year. Operating cash flows were strong in the quarter. However, net cash is down following the executed share buy-back totaling 83 million. During the quarter. The Swedish krona has experienced volatility and weakened against the US dollar, among others, with only minor exchange gains and losses reported as other operating income and expenses. This graph on this slide shows, with gray bars, how the relationship between the US dollar closing rate and the Swedish krona has varied over time. This is read out on the y-axis. The blue dotted line, read out on the y-axis, shows the adjusted operating result. The adjusted operating result, excluding translation exchange effects, is the orange line and gives a more comparable view of the underlying trend. In the table below the graph, you can see that the FX-adjusted operating margin was 28% in the quarter, compared with 26% in the same quarter last year. In the shorter term, the operating margin has been impacted by the commercial investments made in both Europe and the US, and this quarter shows a return to a gradually improved operating margin. As already mentioned, a solid cash conversion has been reported continuously since Q3 2024, with an average cash conversion of 79% visible as the dotted line in this graph, and Q2 this year reports a solid 67% cash conversion. And with this, I hand back over to you.

Torbjörn Sköld
19:09 - 20:36

Thank you. To summarize, Q2 2026 sales grew 30% at constant exchange rates, reflecting steady and consistent progress. Highlights were EUROW growth versus prior year of 26% at constant exchange rates, a strong adjusted operating margin of 29%, and solid cash flow, underscoring the strength of the business and its scalability. As a result of the first half of the year's sales growth of 31% at constant exchange rates. We estimate full-year sales growth to be between 33% and 36% in constant exchange rates. Our confidence in this estimate is based on the underlying run rate coming out of Q2. The new account pipeline that we see with both IDNs as well as distributors. And on top of that, we see the potential positive triggers of the CMS ruling, the SOLARIO study publication, and a CERAMENT V approval. The quarter confirms that the company's position has strengthened and continues to be characterized by relatively low but rapidly increasing market penetration, creating significant room for expansion for many years to come. Now let's open the line for questions.

Operator
20:37 - 20:54

If you wish to ask a question, please dial pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six on your telephone keypad. The next question comes from Eric Castle from Danske Bank. Please go ahead.

Unknown 1
20:55 - 21:37

Hello. Good morning. I wanted some clarification on what you call it. Stop, go. Go. No. Go. Stop. Go. Dynamic that you talked about. Sorry. In the US, on those sort of accounts, is it possible to say if they have some sort of special characteristics. Are they mainly inpatient or outpatient? Do they perform any specific types of procedures? Are they atypical in the amount of procedures that they do? I think any color on how general or niche these accounts are would be helpful to sort of pencil out the outlook and if it applies to everything basically.

Torbjörn Sköld
21:38 - 22:44

Yeah. So what we can see is that it is a handful of accounts. All the accounts are among the top 50 accounts that we have. And we don't see anything related to that. They are not in a special niche or only in one of the three categories. And we also see that they are unrelated to each other. So we do not see a common trend or anything like that. What is also very important is that all of these accounts continue to use our products at a relatively high volume level, albeit at a slightly reduced level compared to Q2 2025. And we have ongoing conversations with all of them to provide arguments for why they should come back to the previous levels. And also, not only that, but grow from there. So that is what we can see. What can we say about those? Those accounts. I don't know if there is anything else that I am missing on that one.

Håkan Johansson
22:44 - 22:57

No. And I think that's fair to say that if we look at that category of large customers and we exclude the handful where we now experience this situation, there is a solid underlying growth among these accounts.

Torbjörn Sköld
22:59 - 22:59

Correct.

Unknown 1
23:01 - 23:37

Okay. Thank you. And my assumption has been that all the clinical data and cost-benefit, etc. is being assessed during the Value Analysis Committee approvals to sort of get into hospital to begin with. Can you shed some light on the arguments that you need to have with hospitals to get them to resume that higher usage and basically not have restrictions? Do they request more clinical data, or are their own clinical outcomes not really reflecting the sort of data that you have produced already? What is the actual pushback from them?

Torbjörn Sköld
23:38 - 24:21

No, typically what we see is that the access comes at different levels of the hospital. It is not that we have convinced one group of administrators and they change their minds. It has to do with that. We increase the volume of usage either in the hospital or a group of hospitals. And they see the increasing number of invoices and the volumes and the amount of money that they spend on CERAMENT. So it is not necessarily a new type of argument or new evidence that is required. It is just to make sure that we get access on more and more levels as we grow the adoption within the accounts.

Unknown 1
24:23 - 25:02

Okay. Thank you. Last question. Is it possible to in some way quantify what it could have been if it wasn't for this sort of dynamic, if those accounts would have performed, say, like the other cohorts that did not see this dynamic. What would the overall growth have been in that case. And that ties into whether you can somehow proactively prevent this dynamic by actively, before that happens, showing the hospital administration more data, or perhaps seeing those codes come into effect by October. Is there something we can do about that?

Torbjörn Sköld
25:02 - 27:38

Great questions. Thank you, Eric. On the first point, we are not going to give you a specific number, but at a high level, if it were not for these handful of accounts, we would be perfectly on plan and exactly in line with what we planned for. So that is what we can say on the second piece; it is a really good topic. And we have invested over the last couple of quarters in our medical education, in our national accounts, and in our health economics teams, etc. So we are building those capabilities. We have done so. And we will continue to do so. And what we saw in the second quarter is that that's exactly the right thing to do. And exactly to your point, that also means being more proactive when we enter accounts to make sure that we don't enter into this go-stop-go cycle, so that we have more of a linear and solid progression, ensuring that we always convince the clinical stakeholders first. That is just a given in the business that we are in, but also that we early on engage them more proactively using the data that we have. And I think there are two aspects in the short term that will really strengthen our case on this one. One is clearly what you mentioned regarding the CMS ruling. Assuming it comes into play, it will be viewed very positively. It should be very positive. That's number one. So of course, we are preparing a lot of work on that to make sure that we have solid material and a rollout plan, and educating not just our users and the clinicians, but also the administrators and the coders at the hospital so that they fully understand and can leverage this. That is number one. Another point is, for example, the upcoming and expected publication of the Solario study. That is a really good piece of evidence that really supports the usage and also the higher cost of CERAMENT compared to alternatives. So I think that's how I would answer those two questions, Eric, if that makes sense.

Unknown 1
27:39 - 27:42

Yeah, great. Thank you so much. I will jump back in the queue.

Operator
27:45 - 27:50

The next question comes from Christopher Lilleberg from ABG Sundal Collier. Please go ahead.

Unknown 1
27:53 - 28:51

Yeah. Thank you. Three questions. First, on the same topic, could you maybe provide a figure? What has your historical success rate been in overturning these types of administrative restrictions, because I gather this is not something entirely new. Secondly, you touched upon the reimbursement changes; is it too early, or have you received any feedback in conversations with customers regarding how positive this could actually be? And then my final question is regarding the selling expenses, which were flat sequentially after having been up quite significantly in the previous two quarters. Should we expect it to remain at this level for the coming quarters, or are you planning additional hiring in the short term that will drive up costs further? Thank you.

Torbjörn Sköld
28:53 - 29:50

Thank you, Christopher. Good questions. So, the first question on the success rate. We have been quite successful with this historically, not 100%, but definitely more than 50%. So I think it's somewhere between 50% to 100% in terms of the success rate. What is positive here is that the dialogues are ongoing. And so, that is the answer to your first question. Reimbursement changes. I think it is a combination of very positive and too early to tell honestly, because it is still a proposed ruling. It has not been decided yet, but the limited feedback that we have is very positive; however, I think it is too early to draw any conclusions on that. Those were the answers to the first two questions. What about selling expenses?

Håkan Johansson
29:50 - 30:19

So about selling expenses. Will these be flattening out? No, I think that given the market potential that remains, we will continue to invest commercially. Do we see and do we have plans that will make big impacts in the shorter term? No. But again, we will stay the course. I am sure that we will report and you will see gradually increasing selling expenses.

Unknown 1
30:22 - 30:47

Yes. Coming back to that, the reason I'm asking is because if we looked at the fourth quarter and first quarter. The sequential increase in operating profit was quite limited despite continued strong sales growth. So just wondering if we could expect, as we saw this quarter, more operational leverage momentum for the remainder of the year sequentially.

Håkan Johansson
30:47 - 30:57

I think that is what you can expect, is that selling expenses as a percentage of sales will continue to come down, and by that, support improved operating leverage going forward.

Unknown 1
30:59 - 31:01

Okay, great. Thank you very much.

Operator
31:06 - 31:10

The next question comes from Matthias from SEB. Please go ahead.

Unknown 2
31:13 - 31:36

Hi. Thank you for taking my questions. Some of them have been asked already, but I will continue a bit on the growth dynamics. When you say that they are applying a stop-and-go process and awaiting results. So, just to be clear, are these results regarding patient outcomes, health economic outcomes, or both? That is the first one.

Torbjörn Sköld
31:38 - 32:49

Okay. Good. So the go-stop-go dynamics typically apply to two parts. One is the clinical that's early phase. That is not what we saw in Q2. But go-stop-go can apply to a clinician wanting to try the product, tries the product in a number of patients, then stops to see the clinical results. And that is one aspect of that which is not what we see in Q2. The other aspect is simply that clinicians start using the product, but the approvals at higher levels in the administration can occur at several different levels depending on the amounts of money that they spend on CERAMENT there. It is not so much that, they want to see the results of the health economic benefits. And so, as Eric Cassell pointed out earlier, it could be a value approval committee. There are many different natures of these in US hospitals. So they want to see the health economic results of it. Number one from other clinics, number two, sometimes in their own clinic. So that is the answer to that question. Yes.

Unknown 2
32:51 - 33:01

Okay. Then I guess that takes a bit of time because the major benefit is, of course, that the patients do not return with infections and so forth. I guess.

Torbjörn Sköld
33:02 - 33:32

Most of the time it is enough that you have a good meeting with the administrators, supported by local key opinion leaders, regional key opinion leaders, and ourselves. That is the most common scenario. So actually, I wouldn't say it would necessarily take a lot of time, but for sure weeks or months to establish these meetings and get the rules in our favor. That is the timing aspect that I have in mind.

Håkan Johansson
33:33 - 33:51

And I think we should not forget that we are talking about high-volume customers. That means that there is plenty of documentation from patients treated at these hospitals that we can benefit from in these discussions.

Unknown 2
33:53 - 34:09

Great. That is a clear answer. And the next question is, did you see the dynamic of those handful of key accounts change anything through the quarter? Or was it the same environment the whole Q2?

Torbjörn Sköld
34:10 - 35:22

I think it's fair to say. And that is also, to the last comment that I made in the presentation, when we talk about the confidence in delivering the 33% to 36%. I think if we look at the run rate coming out of Q2, it looks very positive. There is no doubt about that. So I think the dynamic changed gradually during the quarter to the positive. But again, as we saw in the quarter, it fluctuates and it will fluctuate going forward. But we have good confidence in this going forward. But it is not the first time that it happens, and it is not the last time that it happens. It is simply the nature of the business that we are in. We are growing 30% to 40% in the US. That means that the hospitals spend a lot more money on CERAMENT. We keep our pricing very stable, and we want to be disciplined around that. We don't want to take shortcuts by reducing price just to get an easy approval; we want to maintain that price level and continue to grow. We have seen this in the past, we saw it in Q2, and we will continue to see it going forward.

Unknown 2
35:24 - 35:54

Perfect. Thank you. I will squeeze in the last one. There has been news this week from a major private hospital in the US, citing lower surgery volumes in the second quarter. So I'm just asking here, did you experience any impact in the quarter from a lower overall procedure volume in orthopedics in the US during Q2, or is this not a factor for you? Thank you.

Torbjörn Sköld
35:54 - 36:54

Great question. Yes, we have noted the data points from several different external sources. When we look at market data that is applicable to the indications that we are in, we also see the same data points. But it is difficult to say that we see it in our numbers or to explain our numbers through that lens. With that, I think it is difficult to confirm that that is a factor, and it is also difficult to reject that. That is not a factor simply because we are so small. We are growing 30%. I mean, in the US, even more. And so, to say that our results are due to a slight reduction in volume, I don't think it would be intellectually honest to say that it could be the case, but it could also not be the case. We don't really see it that way.

Unknown 2
36:56 - 36:58

Thank you so much for all the answers.

Operator
37:01 - 37:06

The next question comes from Sten Gustafsson from ABG Sundal Collier. Please go ahead.

Unknown 3
37:08 - 37:37

Good morning. You already answered a lot of questions about the U.S. market. market, but I just want to confirm if I heard you correctly when you said that the momentum during the quarter improved gradually. Is it correct that the growth trend was stronger in June compared to the start of the quarter?

Torbjörn Sköld
37:38 - 38:31

Yeah. I think it's fair to say that when we look at our estimates for the remainder of the year, we base our projections on how we arrive at the 33% to 36% growth target. I think there are a couple of factors. One was the run rate that we saw coming out of Q2. That's number one. So, yes, is the answer to your question. But that's not the only thing, of course. What is also very important is to look at what we have in the pipeline of conversions, customer items and also equally important new distributors that we sign up. So I would say those two factors are the key underlying points in our confidence in the 33 to 36 percent growth range. And on top of that, you have those CMS rulings, this study and CERAMENT V approval.

Unknown 3
38:35 - 38:41

Yeah. And have you heard anything about the publication of the Solorio study and when that will come?

Torbjörn Sköld
38:42 - 39:19

We have the same information that we have given previously, meaning that it has been approved for publication. We have no new news to that, and we expect a publication in the near term, but that is what we said in the last quarterly call, and I hope it is the last quarterly call. I say this, but you never know with these scientific journals; it is out of our control and it is out of the author's control as well. But we will see how it plays out.

Unknown 3
39:20 - 39:56

Sure. Then turning to Europe and the rest of the world, can you provide some detail? Obviously it's great to see the growth rate there. Could you highlight some of the markets where you see particularly strong growth rates? And how are the UK and Germany, which I assume are the largest parts contributing to that growth? And also the new markets where you recently entered, like India and Canada. And so.

Torbjörn Sköld
39:56 - 41:21

Sure. I think what's very positive with Europe is that it's broad across direct and hybrid distributors. It is also broad within the respective countries. I will not quote any numbers. I leave that to Håkan to do if he wants to, but I think high level, in Germany we saw recovery from last year. So both the healthcare market there as well as ourselves have sort of adopted and found our way in this new normal. I think the UK is more neutral. I mean, we saw some recovery earlier in the year and in Q2 it was more neutral. India follows the plan, but it is still quite small. So it's not a material driver of the growth in EUROW. It is more that most of the other countries are just trending in the right way. And we gradually improve in all of them. But also, I think when you look at the EUROW number, you should have taken into account that we came from a relatively speaking lower base last year, but when we adjust for that, it's still a very solid and good growth. So we're very pleased with the performance. I don't know if you have anything else.

Håkan Johansson
41:21 - 42:05

I think to your last point, again, we know that we have soft comparables, but despite Easter in early April, the EUROW region delivered good sequential growth compared to Q1 and provided strong confirmation regarding stability in the UK primary market. Also, there is some realism about the stabilization in Germany and stable growth in all our direct markets, as well as solid and high growth numbers in the markets where we have been investing. So I think that gives a lot of confidence around our strategies outside the US going forward.

Unknown 3
42:07 - 42:08

Thank you.

Operator
42:12 - 42:15

The next question comes from Ed Hall from Stifel. Please go ahead.

Unknown 4
42:18 - 42:39

Good morning guys. Thank you for taking my questions. Apologies for sticking on the US topic. But I just wanted to understand the customer concentration in the US and perhaps the number of accounts that have this dynamic. What channel were they in? And is this in any way related to the Affordable Care Act subsidy expiring? That would be my first question.

Torbjörn Sköld
42:40 - 43:39

Okay. So the number of accounts where we saw the impact in Q2 is a relatively small number. So we state a handful of accounts in the report and we do not provide more specifics than that. That's number one in terms of the channels. No, we pretty much only have one channel. It is an independent sales channel. And there was no sort of pattern there that was related to only one independent sales rep channel or the other. There is no pattern there. And we don't have any information that this sort of fluctuations in the US can be correlated to anything related to the Affordable Care Act. But again, we cannot confirm it and we cannot predict it. That would be my answer to it.

Unknown 4
43:42 - 44:09

That's pretty clear. Thanks. And then I guess maybe just on the updated guidance. I would love to hear your thoughts as we go into H2 and I appreciate it is easier comps. But obviously there is still an underlying acceleration. So I just wanted to understand what underpins your confidence for this guidance. Is it related to the easier comps? Is it a clear acceleration that you are seeing, as any commentary there would be really helpful.

Torbjörn Sköld
44:10 - 45:41

Yeah, sure. It goes back to what I said earlier around why we feel very confident in the 33 to 36 range? It is how we came out of Q2. It is the trend that we saw in Q2. It is the absolute level that we had in terms of run rates. It is also in terms of the product mix. That's, that's number one. Number two is also, when we look at the pipeline of call it new accounts and new ideas, it looks very healthy compared to our historic numbers. And also, when we look at the pipeline of new distributors, that looks also very healthy. So those are the three key points to that. And on top of that, if you overlay, this is sort of out of our control and it is difficult to get the timing on it. But those first three things, these are within our control. But out of our control is the CMS ruling. It is the publication of the SOLARIO study. And it is also the CERAMENT G. Sorry. CERAMENT V approval is in that order of magnitude of potential impact in the second half of the year. That is what is building our confidence in the new guidance.

Unknown 4
45:43 - 46:04

Perfect. Now that makes a lot of sense. And then maybe just finally, back on the US, of the three US segments that you have broken out, could you talk about which segments are performing above expectations or in line with expectations for the first half of the year? Or maybe put it another way, what is really driving the results today?

Torbjörn Sköld
46:05 - 46:54

Yeah. I am going to give the boring answer on this one. I think all three segments delivered in line with plan. When we look at the numbers and the product mix, we see and hear a lot of positive feedback on the fact that we are entering still at a very early stage, but that we are entering Revision Arthroplasty. But that is more what I would call noise, qualitative feedback, and in terms of the numbers in the quarter, all three segments delivered according to plan and spine also delivered according to plan, but it is such a small number, so it does not really change the overall picture.

Unknown 4
46:56 - 46:59

Perfect. Thank you very much and congrats.

Operator
47:01 - 47:14

As a reminder, if you wish to ask a question, please dial pound key five on your telephone keypad. The next question comes from Christopher Lilleberg from NB Carnegie. Please go ahead.

Unknown 1
47:17 - 47:45

Yeah. Two additional questions, if there is time. First, cash flow continues to be strong. I am just wondering how you view the share buy-back mandate you have and the need to keep a substantial amount of cash on the balance sheet. And the second question is Germany. Is that market back to growth, or has it just stabilized at a lower level? Thank you.

Håkan Johansson
47:46 - 48:17

So thank you, Christopher. And I will start with the first question. Again, it is positive to see a continued underlying positive cash flow, which provides us with the necessary funds to continue reinvesting in the business. We talked about continued commercial investments, etc. But again, it also opens up for a more utilization of the mandate that was given by the AGM in May to continue buying back shares.

Torbjörn Sköld
48:19 - 48:47

Good. And since you stopped, I assume I will take the second question. Thank you. No. It's good. On Germany, I would categorize it more as stabilizing than growing, but clearly going in the right direction. And of course, as we develop month over month, it is not black and white, but we are still more in the stabilization phase than the growth phase.

Unknown 1
48:51 - 48:52

Great. Thank you.

Operator
48:56 - 49:03

There are no more questions at this time. So I hand the conference back to the speakers for any written questions and closing comments.

Håkan Johansson
49:04 - 49:31

We have a few questions on the web. Most of them have been answered already. But there is one question that has not been covered in the call, and that is back to the communication we made on level one trauma centers and how they are progressing. After the increase in access in 2025. So a few words on that one.

Torbjörn Sköld
49:31 - 51:47

Sure. No, I think progress is solid according to plan really. So we focus more on increasing the adoption in those centers where we managed to get access rather than necessarily going for more. But we are progressing well, and we are pleased with the performance. But again, it is a very early phase. I think that is one question right from the web. What is this one? Then there is another one. What triggered the guidance downgrade? What triggered the downgrade of your guidance for this year? And I would say it is more a reflection that we have now two quarters in the books. We grew 31% in the first half year compared to the first half year in 2025, where we grew 40%. It is really to be as transparent and granular with the market on what we see, what we feel, and what we think for the remainder of the year. That is really the background for the updated guidance. What is this? If the De Novo process continues as planned, when do you expect to be able to make first sales of CERAMENT V in the US? Is that included in the guidance? Okay, great. So we plan to submit our answers to the FDA no later than the end of August. Then it is really up to the FDA to say yes, no, or something in between. But given that, let's say that we submit at the end of August, it is going to have very little material impact. Well, it is going to have very little impact on our numbers for this year. So we have not taken into account any CERAMENT V in the updated guidance. Is that all? No further questions.

Håkan Johansson
51:47 - 51:48

No further questions.

Torbjörn Sköld
51:48 - 52:02

No, nothing on the chat. Nope. Okay. So with that, thank you all for your attention and wish you a great rest of the day and a fantastic summer for those of you who have vacations, thank you very much.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…